Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


04.09.2017

4 BJU Int
2 BMC Cancer
1 BMC Urol
3 Br J Cancer
1 Br J Radiol
1 Cancer
1 Cancer Lett
1 Clin Cancer Res
5 Eur Urol
1 Int J Oncol
1 Int J Radiat Oncol Biol Phys
2 J Clin Oncol
1 J Urol
5 Nat Rev Urol
2 PLoS One
6 Prostate
2 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BJU Int


  1. Abstracts of the 18th Asia-Pacific Prostate Cancer Conference 2017, Australia, 30 August-02 September 2017.
    BJU Int. 2017;120 Suppl 1:5-23.
    PubMed     Text format    

  2. KIM PJ, Park JY, Kim HG, Cho YM, et al
    Dishevelled segment polarity protein 3 (DVL3): a novel and easily applicable recurrence predictor in localised prostate adenocarcinoma.
    BJU Int. 2017;120:343-350.
    PubMed     Text format     Abstract available

  3. JACKSON WC, Desai NB, Abugharib AE, Tumati V, et al
    Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study.
    BJU Int. 2017;120:351-357.
    PubMed     Text format     Abstract available

  4. STEURER S, Rico SD, Simon R, Minner S, et al
    High concordance of findings obtained from transgluteal magnetic resonance imaging - and transrectal ultrasonography-guided biopsy as compared with prostatectomy specimens.
    BJU Int. 2017;120:365-376.
    PubMed     Text format     Abstract available


    BMC Cancer

  5. KINNUNEN PTT, Murtola TJ, Talala K, Taari K, et al
    Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer.
    BMC Cancer. 2017;17:585.
    PubMed     Text format     Abstract available

  6. TANAKA N, Asakawa I, Nakai Y, Miyake M, et al
    Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer.
    BMC Cancer. 2017;17:573.
    PubMed     Text format     Abstract available


    BMC Urol

  7. MIYAZAWA Y, Sekine Y, Syuto T, Nomura M, et al
    A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients.
    BMC Urol. 2017;17:70.
    PubMed     Text format     Abstract available


    Br J Cancer

  8. SAMARENDRA H, Jones K, Petrinic T, Silva MA, et al
    A meta-analysis of CXCL12 expression for cancer prognosis.
    Br J Cancer. 2017;117:124-135.
    PubMed     Text format     Abstract available

  9. MARTIKAINEN M, Ruotsalainen J, Tuomela J, Harkonen P, et al
    Oncolytic alphavirus SFV-VA7 efficiently eradicates subcutaneous and orthotopic human prostate tumours in mice.
    Br J Cancer. 2017;117:51-55.
    PubMed     Text format     Abstract available

  10. PAL D, Suman S, Kolluru V, Sears S, et al
    Inhibition of autophagy prevents cadmium-induced prostate carcinogenesis.
    Br J Cancer. 2017;117:56-64.
    PubMed     Text format     Abstract available


    Br J Radiol

  11. FLUX GD
    Imaging and dosimetry for radium-223: the potential for personalized treatment.
    Br J Radiol. 2017 Jun 27:20160748. doi: 10.1259/bjr.20160748.
    PubMed     Text format     Abstract available


    Cancer

  12. LEWIS DR, Chen HS, Cockburn MG, Wu XC, et al
    Early estimates of SEER cancer incidence, 2014.
    Cancer. 2017;123:2524-2534.
    PubMed     Text format     Abstract available


    Cancer Lett

  13. DATTA A, Kim H, Lal M, McGee L, et al
    Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells.
    Cancer Lett. 2017 Aug 24. pii: S0304-3835(17)30507.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  14. BELTRAN H, Wyatt AW, Chedgy E, Donoghue A, et al
    Impact of therapy on genomics and transcriptomics in high-risk prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
    Clin Cancer Res. 2017 Aug 25. pii: clincanres.1034.2017.
    PubMed     Text format     Abstract available


    Eur Urol

  15. LOEB S, Zhou Q, Siebert U, Rochau U, et al
    Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
    Eur Urol. 2017 Aug 22. pii: S0302-2838(17)30642.
    PubMed     Text format     Abstract available

  16. DE BONO JS, Chowdhury S, Feyerabend S, Elliott T, et al
    Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for >/=24 weeks in Europe.
    Eur Urol. 2017 Aug 22. pii: S0302-2838(17)30664.
    PubMed     Text format     Abstract available

  17. BORGMANN H, Lallous N, Ozistanbullu D, Beraldi E, et al
    Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Eur Urol. 2017 Aug 26. pii: S0302-2838(17)30698.
    PubMed     Text format     Abstract available

  18. TAKEDA T, Tin AL, Corradi RB, Mamoor M, et al
    Topography of Prostate Cancer Recurrence After Radiation Therapy: A Detailed Mapping Study of Salvage Radical Prostatectomy Specimens.
    Eur Urol. 2017 Aug 26. pii: S0302-2838(17)30691.
    PubMed     Text format     Abstract available

  19. EGGER SJ, Calopedos RJ, O'Connell DL, Chambers SK, et al
    Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer.
    Eur Urol. 2017 Aug 26. pii: S0302-2838(17)30699.
    PubMed     Text format     Abstract available


    Int J Oncol

  20. LU L, Li K, Mao YH, Qu H, et al
    Gold-chrysophanol nanoparticles suppress human prostate cancer progression through inactivating AKT expression and inducing apoptosis and ROS generation in vitro and in vivo.
    Int J Oncol. 2017 Aug 10. doi: 10.3892/ijo.2017.4095.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  21. DADKHAH H, Hopfensperger KM, Kim Y, Wu X, et al
    Multisource Rotating Shield Brachytherapy Apparatus for Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017 Jun 20. pii: S0360-3016(17)31057.
    PubMed     Text format     Abstract available


    J Clin Oncol

  22. SPRATT DE, Yousefi K, Deheshi S, Ross AE, et al
    Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.
    J Clin Oncol. 2017;35:1991-1998.
    PubMed     Text format     Abstract available

  23. BURRIS HA, Infante JR, Ansell SM, Nemunaitis JJ, et al
    Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
    J Clin Oncol. 2017;35:2028-2036.
    PubMed     Text format     Abstract available


    J Urol

  24. CASTELLO A, Boldo E, Amiano P, Castano-Vinyals G, et al
    Mediterranean dietary pattern is associated to low risk of aggressive prostate cancer: MCC-Spain study.
    J Urol. 2017 Aug 22. pii: S0022-5347(17)77385-5. doi: 10.1016/j.juro.2017.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  25. THOMA C
    Prostate cancer: Postdiagnosis statin use reduces mortality.
    Nat Rev Urol. 2017 Aug 31. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  26. THOMA C
    Prostate cancer: Stratifying salvage radiotherapy utility.
    Nat Rev Urol. 2017 Aug 31. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  27. STONE L
    Prostate cancer: Mastering transcription: TMPRSS2-ERG and the cis-regulatory landscape.
    Nat Rev Urol. 2017 Aug 31. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  28. FENNER A
    Prostate cancer: IGF2 imprinting loss promotes cancer.
    Nat Rev Urol. 2017 Aug 31. doi: 10.1038/nrurol.2017.
    PubMed     Text format    

  29. STONE L
    Prostate cancer: Place your BETs.
    Nat Rev Urol. 2017 Aug 31. doi: 10.1038/nrurol.2017.
    PubMed     Text format    


    PLoS One

  30. LUCAS JL, Tacheny EA, Ferris A, Galusha M, et al
    Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy.
    PLoS One. 2017;12:e0182739.
    PubMed     Text format     Abstract available

  31. ZHOU J, Gao S, Hsieh CL, Malla M, et al
    Peptide B targets soluble guanylyl cyclase alpha1 and kills prostate cancer cells.
    PLoS One. 2017;12:e0184088.
    PubMed     Text format     Abstract available


    Prostate

  32. GINSBURG KB, Elshafei A, Yu C, Jones JS, et al
    Avoidance of androgen deprivation therapy in radiorecurrent prostate cancer as a clinically meaningful endpoint for salvage cryoablation.
    Prostate. 2017 Aug 29. doi: 10.1002/pros.23406.
    PubMed     Text format     Abstract available

  33. SOEKMADJI C, Corcoran NM, Oleinikova I, Jovanovic L, et al
    Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.
    Prostate. 2017 Aug 29. doi: 10.1002/pros.23403.
    PubMed     Text format     Abstract available

  34. MIYATA Y, Nakamura Y, Yasuda T, Matsuo T, et al
    Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.
    Prostate. 2017 Aug 28. doi: 10.1002/pros.23402.
    PubMed     Text format     Abstract available

  35. LIU L, Li E, Luo L, Zhao S, et al
    PSCA regulates IL-6 expression through p38/NF-kappaB signaling in prostate cancer.
    Prostate. 2017 Aug 28. doi: 10.1002/pros.23399.
    PubMed     Text format     Abstract available

  36. SUH JH, Park JH, Lee C, Moon KC, et al
    Intrafocal heterogeneity of ERG protein expression and gene fusion pattern in prostate cancer.
    Prostate. 2017 Aug 28. doi: 10.1002/pros.23405.
    PubMed     Text format     Abstract available

  37. HENDRIKS RJ, van der Leest MMG, Dijkstra S, Barentsz JO, et al
    A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection.
    Prostate. 2017 Aug 29. doi: 10.1002/pros.23401.
    PubMed     Text format     Abstract available


    Urology

  38. OROM H, Biddle C, Underwood W 3rd, Homish GG, et al
    Racial/Ethnic and Socioeconomic Disparities in Prostate Cancer Survivors' Prostate-Specific Quality of Life.
    Urology. 2017 Aug 22. pii: S0090-4295(17)30866.
    PubMed     Text format     Abstract available

  39. FRIEDL A, Stangl K, Bauer W, Kivaranovic D, et al
    Prostate-Specific Antigen Parameters and Prostate Health Index Enhance Prostate Cancer Prediction with the in-Bore 3-T MRI-Guided Transrectal Targeted Prostate Biopsy after Negative 12-Core Biopsy.
    Urology. 2017 Aug 24. pii: S0090-4295(17)30880.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: